Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ASEAN Makes Slow But Steady Progress Toward Harmonization Of Pharmaceutical Regulations

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - The Association of Southeast Asian Nations is slated to implement common technical documents starting this year as part of "harmonized" pharmaceutical regulations in the region, which could benefit consumers by 2010

You may also be interested in...



Common Language For Regulatory Harmonization Takes Shape In Asia, But Mutual Recognition Unlikely Anytime Soon

Regulators, industry and health care agencies are increasingly using the same language to describe efforts at harmonization for drug approvals and manufacturing. But even though mutual recognition agreements on drug approvals are the “ultimate goal,” getting there in Asia could take a decade or more.

Would New Drug Launches Speed Up With A Pan-Asia Regulatory Framework? - Biopharma Asia Conference

SINGAPORE - As diseases like diabetes and cardiovascular complications - previously believed to be more prevalent in Western nations - are progressively spreading East to places like India and China, Asia-based pharmaceutical companies are pushing for a pan-Asian regulatory regime that can benefit its people with clear and obtainable goals

Would New Drug Launches Speed Up With A Pan-Asia Regulatory Framework? - Biopharma Asia Conference

SINGAPORE - As diseases like diabetes and cardiovascular complications - previously believed to be more prevalent in Western nations - are progressively spreading East to places like India and China, Asia-based pharmaceutical companies are pushing for a pan-Asian regulatory regime that can benefit its people with clear and obtainable goals

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070215

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel